Solid Biosciences Inc. is a clinical-stage biotechnology company dedicated to creating gene therapies for devastating genetic disorders. The company's pipeline includes lead candidates such as SGT-003 for Duchenne muscular dystrophy (DMD) and SGT-212 for Friedreich's ataxia, alongside programs targeting catecholaminergic polymorphic ventricular tachycardia (CPVT) and dilated cardiomyopathy. In addition to its therapeutic candidates, Solid Biosciences develops platform technologies, including proprietary adeno-associated virus (AAV) capsid libraries and dual gene expression systems, to improve gene therapy delivery across the industry. Founded by individuals directly impacted by DMD, the company operates primarily in the United States and seeks to unite experts in science, technology, and disease management to address significant unmet medical needs.
